Evaluation of the therapeutic effects of Convalescent Plasma (CP) of recovered people from Covid-19 in improving clinical and laboratory symptoms of hospitalized patients

Inclusion criteria:

(As a plasma donor): Complete resolution of COVID-19 disease symptoms at least 14 days prior to donation. (As a plasma donor): Donors do not have a history of blood or blood product transfusion (As a plasma donor): COVID-19 neutralizing antibody titers be greater than 1:320 (If possibly checked) (As a plasma donor): The donor's age be between 25 and 55 years old (As a plasma donor): Negative results for COVID-19 by PCR (As a plasma donor): Be in suitable general health condition for plasmapheresis (As a plasma recipient): Patients admitted to the ICU who is receipt of mechanical invasive or non-invasive ventilation, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300mmHg (93%). Current receipt of intravenous vasoactive medications to maintain mean arterial pressure >65 mmHg (As a plasma recipient): Respiratory frequency ≥ 30/min (As a plasma recipient): Laboratory-confirmed COVID-19 infection (by real time PCR).

Exclusion criteria:

(As a plasma recipient): Negative real-time PCR from respiratory secretions or blood within 48 h prior to CP transfusion (As a plasma recipient): History of allergic reaction to blood or plasma products (As a plasma recipient): Known IgA deficiency

Target sample size: 12